A heartfelt thank you to the exhibitors & sponsors that support the conference
Servier, a global pharmaceutical group
Our vocation: We are committed to therapeutic progress to serve patient needs.
Founded to serve health, Servier is a global group governed by a non-profit Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,900 employees of the Group are committed to this shared vocation, source of inspiration every day.
As a leader in cardiology, Servier’s ambition is to become a focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology.
Neuroscience and immuno-inflammatory diseases are the area of focus as this is where we believe we can have the biggest impact. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.
In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.
In Research & Innovation, our aim is clear—to accelerate the pace of research and efforts to develop new therapeutic solutions guided by a long-term vision.
Servier’s independence from market forces means we can invest heavily in R&D to innovate and develop new medicines. That is why we invest over 20% of our sales revenue (excl. generic medicines) each year in R&D.
Headquartered in France, Servier relies on a strong geographical footprint in close to 140 countries and achieved a revenue of €6.9 billion for the financial year ending September 2025.
Marginum is a Finnish medical device manufacturer and market forerunner in intra-operative aspirate tissue monitoring systems.
Our technology analyses the fluorescence of resected surgical tissue flowing through the suction tube and detects fluorescence indicating malignant tissue. When fluorescence is detected, the surgeon is notified with near-real-time, objective, and precise feedback.
Marginum’s products support intra-operative decision-making by providing increased detection of fluorescence directly from aspirated tissue. They integrate seamlessly with existing surgical workflows and are compatible with the most common ultrasonic aspirator systems.
HIVEN® Aspirate Tissue Detector, an MDR CE-marked Class IIb medical device, provides detection of 5-ALA-based fluorescence from aspirated tissue in high-grade glioma surgeries. HIVEN® is now available in European markets through our distributors.
Learn more at www.marginum.com.
For five decades, Elekta’s helped advance precision in cancer care, from pioneering radiosurgery to leading the move into adaptive radiotherapy today.
Elekta Esprit the latest Leksell Gamma Knife® is designed to do more than just preserve life—it’s designed to preserve a whole lifetime.
Continuing the Leksell Gamma Knife tradition, its submillimeter accuracy redefines what is thought possible in stereotactic radiosurgery.
By treating even the smallest, most challenging intracranial targets while protecting essential healthy tissue, you can effectively treat the patient while keeping their self, safe.
Elekta Esprit is the perfect combination of precision and performance, providing a best-in-class treatment experience for you and your patient.
Directed from different angles, the beams cross over at the affected area of your brain, delivering the radiation dose precisely to the target while protecting the surrounding healthy tissue.
Since there is no need for a general anesthetic or open surgery, and there are only mild or no side effects, you’ll most likely go home the same day as your treatment and quickly return to normal activities.
Leading radiosurgery centers around the world choose Gamma Knife for its accuracy and excellent outcomes. About 90,000 patients are treated using Gamma Knife radiosurgery every year.
Who we are
Oxford Nanopore Technologies plc was founded in 2005 as a spin-out from the University of Oxford. The company now employs more than 1000 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation.
The technology
Oxford Nanopore has developed a new generation of DNA/RNA sequencing technology. It is the only sequencing technology that offers real-time analysis (for rapid insights), in fully scalable formats from pocket to population scale, that can analyse native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths.
PromethION is the largest format for nanopore sequencing, designed to offer on-demand use of up to 48 Flow Cells – capable of delivering more than 10 Tb of sequence data in a full run, and is now being used in population-scale sequencing projects. The palm sized PromethION 2 makes high-output nanopore sequencing broadly accessible.
